Status:
COMPLETED
Liquid Biopsy in Lung Cancer
Lead Sponsor:
Samsung Medical Center
Conditions:
Lung Cancer (Diagnosis)
Circulating Tumor Cell
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.
Detailed Description
The peripheral blood and tumor tissue samples are collected from the participants.CTC and ctDNA are analyzed from the blood samples.
Eligibility Criteria
Inclusion
- Patients with histology-proven lung cancer or a clinical suspicion of lung cancer
- Age \>=18, \< 80 years
- No previous history of cancer treatment within 5 years
- Patients who agree to participate
Exclusion
- Patients who have been diagnosed with malignancy within 5 years
- Patients with previous history of lung cancer
- Patients who have uncontrolled coagulopathy
Key Trial Info
Start Date :
March 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 11 2019
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT03479099
Start Date
March 12 2018
End Date
March 11 2019
Last Update
August 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06278